Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-09-2021 | Glioma | Original Article

¹⁸F-Boramino acid PET/CT in healthy volunteers and glioma patients

Authors: Zhu Li, Ziren Kong, Junyi Chen, Jiyuan Li, Nan Li, Zhi Yang, Yu Wang, Zhibo Liu

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 10/2021

Abstract

Purpose

In this work, the safety, biodistribution, and radiation dosimetry of large neutral amino acid transporter type-1 (LAT-1) targeting PET tracer ¹⁸F-trifluorobborate-derived tyrosine (denoted as ¹⁸F-FBY) has been investigated. It is designed as a first-in-human study in healthy volunteers and to assay LAT-1 expression level in glioma patients.

Methods

Six healthy volunteers (3 M, 3 F) underwent whole-body PET acquisitions at multiple time points after bolus injection of ¹⁸F-FBY. Regions of interest (ROIs) were mapped manually on major organs, and then the time-activity curves (TACs) were obtained. Dosimetry was calculated with the OLINDA/EXM software. Thirteen patients who were suspected of glioma were scanned with PET/CT at 30 min after ¹⁸F-FBY injection. Within 7 days after PET/CT, the tumor was removed surgically, and LAT-1 immunohistochemical staining for LAT-1 was performed on tumor samples and correlated with ¹⁸F-FBY PET imaging.

Results

¹⁸F-FBY was well tolerated by all healthy volunteers, and no adverse symptoms were observed or reported. ¹⁸F-FBY is rapidly cleared from the blood circulation and excreted mainly through the kidneys and urinary tract. The effective dose (ED) was 0.0039 ± 0.0006 mSv/MBq. In 14 surgical confirmed gliomas (one of the patiens had two gliomas), ¹⁸F-FBY uptake increased consistently with tumor grade, with maximum standard uptake values (SUV_max) of 0.28 ± 0.14 and 2.84 ± 0.46 and tumor-to-normal contralateral activity (T/N) ratio of 2.30 ± 1.26 and 24.56 ± 6.32 in low- and high-grade tumors, respectively. In addition to the significant difference in the uptakes between low- and high-grade gliomas (P < 0.001), the immunohistochemical staining confirmed the positive correlations between the SUV_max, LAT-1 expression (r² = 0.80, P < 0.001), and Ki-67 labeling index (r² = 0.79, P < 0.001).

Conclusion

¹⁸F-FBY is a PET tracer with favorable dosimetry profile and pharmacokinetics. It has the potential to assay LAT-1 expression in glioma patients and may provide imaging guidance for further boron neutron capture therapy of gliomas.

Trial registration

clinicaltrials.gov (NCT03980431)

Available only for authorised users

Geier EG, Schlessinger A, Fan H, et al. Structure-based ligand discovery for the large-neutral amino acid transporter 1, LAT-1. Proc Natl Acad Sci U S A. 2013;110:5480–5.PubMedPubMedCentralCrossRef

Kaira K, Oriuchi N, Imai H, et al. Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. Br J Cancer. 2008;98:742–8.PubMedPubMedCentralCrossRef

Haining Z, Kawai N, Miyake K, et al. Relation of LAT1/4F2hc expression with pathological grade, proliferation and angiogenesis in human gliomas. BMC Clin Pathol. 2012;12:4.PubMedPubMedCentralCrossRef

Kobayashi K, Ohnishi A, Promsuk J, et al. Enhanced tumor growth elicited by L-type amino acid transporter 1 in human malignant glioma cells. Neurosurgery. 2008;62:493–503 discussion 503-494.PubMedCrossRef

Detta A, Cruickshank GS. L-amino acid transporter-1 and boronophenylalanine-based boron neutron capture therapy of human brain tumors. Cancer Res. 2009;69:2126–32.PubMedCrossRef

Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803–20.PubMedCrossRef

Yang Y, Hernandez R, Rao J, et al. Targeting CD146 with a <sup>64</sup>Cu-labeled antibody enables in vivo immunoPET imaging of high-grade gliomas. Proc Natl Acad Sci U S A. 2015;112:E6525.PubMedPubMedCentralCrossRef

Yanagida O, Kanai Y, Chairoungdua A, et al. Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta. 2001;1514:291–302.PubMedCrossRef

Puris E, Gynther M, Auriola S, Huttunen KM. L-type amino acid transporter 1 as a target for drug delivery. Pharm Res. 2020;37:88.PubMedPubMedCentralCrossRef

10.

Papp L, Pötsch N, Grahovac M, et al. Glioma survival prediction with combined analysis of in vivo 11C-MET PET features, ex vivo features, and patient features by supervised machine learning. J Nucl Med. 2018;59:892–9.PubMedCrossRef

11.

Chen W, Silverman DH, Delaloye S, et al. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med. 2006;47:904–11.PubMed

12.

Rapp M, Heinzel A, Galldiks N, et al. Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma. J Nucl Med. 2013;54:229–35.PubMedCrossRef

13.

Ting R, Adam MJ, Ruth TJ, Perrin DM. Arylfluoroborates and alkylfluorosilicates as potential PET imaging agents: high-yielding aqueous biomolecular 18F-labeling. J Am Chem Soc. 2005;127:13094–5.PubMedCrossRef

14.

Liu Z, Li Y, Lozada J, et al. Kit-like 18F-labeling of RGD-19F-arytrifluroborate in high yield and at extraordinarily high specific activity with preliminary in vivo tumor imaging. Nucl Med Biol. 2013;40:841–9.PubMedCrossRef

15.

Liu Z, Pourghiasian M, Radtke MA, et al. An organotrifluoroborate for broadly applicable one-step 18F-labeling. Angew Chem Int Ed Eng. 2014;53:11876–80.CrossRef

16.

Lau J, Liu Z, Lin KS, et al. Trimeric radiofluorinated sulfonamide derivatives to achieve in vivo selectivity for carbonic anhydrase IX-targeted PET imaging. J Nucl Med. 2015;56:1434–40.PubMedCrossRef

17.

Liu Z, Li Y, Lozada J, et al. Stoichiometric leverage: rapid 18F-aryltrifluoroborate radiosynthesis at high specific activity for click conjugation. Angew Chem Int Ed Eng. 2013;52:2303–7.CrossRef

18.

Liu Z, Lin KS, Bénard F, et al. One-step (18)F labeling of biomolecules using organotrifluoroborates. Nat Protoc. 2015;10:1423–32.PubMedPubMedCentralCrossRef

19.

Liu Z, Pourghiasian M, Bénard F, Pan J, Lin KS, Perrin DM. Preclinical evaluation of a high-affinity 18F-trifluoroborate octreotate derivative for somatostatin receptor imaging. J Nucl Med. 2014;55:1499–505.PubMedCrossRef

20.

Chen J, Li C, Hong H, et al. Side chain optimization remarkably enhances the in vivo stability of (18)F-labeled glutamine for tumor imaging. Mol Pharm. 2019;16:5035–41.PubMedCrossRef

21.

Liu Z, Chen H, Chen K, et al. Boramino acid as a marker for amino acid transporters. Sci Adv. 2015;1:e1500694.PubMedPubMedCentralCrossRef

22.

Yang X, Liu Z, Zhang H, et al. Preclinical evaluation of an (18)F-trifluoroborate methionine derivative for glioma imaging. Eur J Nucl Med Mol Imaging. 2018;45:585–92.PubMedCrossRef

23.

Liu H, Han Y, Li J, et al. (18)F-alanine derivative serves as an ASCT2 marker for cancer imaging. Mol Pharm. 2018;15:947–54.PubMedCrossRef

24.

Li J, Shi Y, Zhang Z, et al. A metabolically stable boron-derived tyrosine serves as a theranostic agent for positron emission tomography guided boron neutron capture therapy. Bioconjug Chem. 2019;30:2870–8.PubMedCrossRef

25.

Wang Q, Wang Y, Ding J, et al. A bioorthogonal system reveals antitumour immune function of pyroptosis. Nature. 2020;579:421–6.PubMedCrossRef

26.

Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023–7.PubMed

27.

Kessler RM, Seibyl J, Cowan RL, et al. Radiation dosimetry of (18)F-FPEB in humans. J Nucl Med. 2014;55:1119–21.PubMedCrossRef

28.

Mittra ES, Goris ML, Iagaru AH, et al. Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging α(v)β(3) integrin levels. Radiology. 2011;260:182–91.PubMedPubMedCentralCrossRef

29.

Cuylen S, Blaukopf C, Politi AZ, et al. Ki-67 acts as a biological surfactant to disperse mitotic chromosomes. Nature. 2016;535:308–12.PubMedPubMedCentralCrossRef

30.

Johannessen AL, Torp SH. The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas. Pathol Oncol Res. 2006;12:143–7.PubMedCrossRef

31.

Neder L, Colli BO, Machado HR, Carlotti CG Jr, Santos AC, Chimelli L. MIB-1 labeling index in astrocytic tumors--a clinicopathologic study. Clin Neuropathol. 2004;23:262–70.PubMed

32.

Chen WJ, He DS, Tang RX, Ren FH, Chen G. Ki-67 is a valuable prognostic factor in gliomas: evidence from a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2015;16:411–20.PubMedCrossRef

33.

Kong Z, Li J, Liu Z, et al. Radiomics signature based on FDG-PET predicts proliferative activity in primary glioma. Clin Radiol. 2019;74:815.e815–23.CrossRef

34.

Liesche F, Lukas M, Preibisch C, et al. (18)F-Fluoroethyl-tyrosine uptake is correlated with amino acid transport and neovascularization in treatment-naive glioblastomas. Eur J Nucl Med Mol Imaging. 2019;46:2163–8.PubMedCrossRef

35.

Katsanos AH, Alexiou GA, Fotopoulos AD, Jabbour P, Kyritsis AP, Sioka C. Performance of 18F-FDG, 11C-methionine, and 18F-FET PET for glioma grading: a meta-analysis. Clin Nucl Med. 2019;44:864–9.PubMedCrossRef

36.

Debus C, Afshar-Oromieh A, Floca R, et al. Feasibility and robustness of dynamic (18)F-FET PET based tracer kinetic models applied to patients with recurrent high-grade glioma prior to carbon ion irradiation. Sci Rep. 2018;8:14760.PubMedPubMedCentralCrossRef

37.

Unterrainer M, Schweisthal F, Suchorska B, et al. Serial 18F-FET PET imaging of primarily 18F-FET-negative glioma: does it make sense? J Nucl Med. 2016;57:1177–82.PubMedCrossRef

38.

Habermeier A, Graf J, Sandhöfer BF, Boissel JP, Roesch F, Closs EI. System L amino acid transporter LAT1 accumulates O-(2-fluoroethyl)-L-tyrosine (FET). Amino Acids. 2015;47:335–44.PubMedCrossRef

39.

Dunet V, Pomoni A, Hottinger A, Nicod-Lalonde M, Prior JO. Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis. Neuro-Oncology. 2016;18:426–34.PubMedCrossRef

40.

Wongthai P, Hagiwara K, Miyoshi Y, et al. Boronophenylalanine, a boron delivery agent for boron neutron capture therapy, is transported by ATB0,+, LAT1 and LAT2. Cancer Sci. 2015;106:279–86.PubMedPubMedCentralCrossRef

41.

Grosu AL, Astner ST, Riedel E, et al. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases. Int J Radiat Oncol Biol Phys. 2011;81:1049–58.PubMedCrossRef

42.

Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med. 2001;42:432–45.PubMed

43.

Chen F, Zhang Y, Cai W. Molecular MRI of VEGFR-2 reveals intra-tumor and inter-tumor heterogeneity. Am J Nucl Med Mol Imaging. 2013;3:312–6.PubMedPubMedCentral

Title: 18F-Boramino acid PET/CT in healthy volunteers and glioma patients
Authors: Zhu Li
Ziren Kong
Junyi Chen
Jiyuan Li
Nan Li
Zhi Yang
Yu Wang
Zhibo Liu
Publication date: 01-09-2021
Publisher: Springer Berlin Heidelberg
Keywords: Glioma
Glioma
Glioma
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 10/2021
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-021-05212-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

¹⁸F-Boramino acid PET/CT in healthy volunteers and glioma patients

Abstract

Purpose

Methods

Results

Conclusion

Trial registration

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Trial registration

Please log in to get access to this content

Other articles of this Issue 10/2021

Reply to Paulo Schiavom Duarte

[68Ga]Ga-PSMA-HBED-CC PET/CT demonstrates to be superior to ceCT in detecting early treatment response in metastatic clear cell renal cell carcinoma

C. Tinoco Mesquita, M. F. Rezende: Nuclear Cardiology Basic and Advanced Concepts in Clinical Practice

Intravital microscopy of tumor vessel morphology and function using a standard fluorescence microscope

The importance of lung hyperperfusion patterns in COVID-19-related AVDS

Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223